2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for …
Juvenile idiopathic arthritis (JIA) is defined by the International League of Associations for
Rheumatology (ILAR) as arthritis of unknown etiology that begins before the sixteenth birthday …
Rheumatology (ILAR) as arthritis of unknown etiology that begins before the sixteenth birthday …
Juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting for
>6 weeks with onset before 16 years of age. JIA is the most common chronic inflammatory …
>6 weeks with onset before 16 years of age. JIA is the most common chronic inflammatory …
2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical …
… (level D), or tocilizumab (level D). MTX or leflunomide was recommended for patients with
an MD global 5 and an AJC 0, only after a trial of an IL-1 inhibitor or tocilizumab (level C) (40). …
an MD global 5 and an AJC 0, only after a trial of an IL-1 inhibitor or tocilizumab (level C) (40). …
[HTML][HTML] Etanercept in children with polyarticular juvenile rheumatoid arthritis
DJ Lovell, EH Giannini, A Reiff… - … England Journal of …, 2000 - Mass Medical Soc
Background We evaluated the safety and efficacy of etanercept, a soluble tumor necrosis
factor receptor (p75):Fc fusion protein, in children with polyarticular juvenile rheumatoid …
factor receptor (p75):Fc fusion protein, in children with polyarticular juvenile rheumatoid …
Preliminary definition of improvement in juvenile arthritis
… Ann Rheum Dis (in press) Howe S, Levinson J, Shear E, Hartner S, McGirr G, Schulte M,
Lovell D: Development of a disability measurement tool for juvenile rheumatoid arthritis: the …
Lovell D: Development of a disability measurement tool for juvenile rheumatoid arthritis: the …
2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American …
…, T Kitoh, K Lehmberg, DJ Lovell… - Arthritis & …, 2016 - Wiley Online Library
Objective To develop criteria for the classification of macrophage activation syndrome (MAS)
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process, …
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process, …
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal‐onset multisystem inflammatory disease (NOMID): A …
…, K Schikler, H Hoffman, DJ Lovell… - Arthritis & …, 2002 - Wiley Online Library
Objective Neonatal‐onset multisystem inflammatory disease (NOMID; also known as chronic
infantile neurologic, cutaneous, articular [CINCA] syndrome) is characterized by fever, …
infantile neurologic, cutaneous, articular [CINCA] syndrome) is characterized by fever, …
[HTML][HTML] Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
Background Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid
arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF …
arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF …
[HTML][HTML] Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis
…, N Wulffraat, Z Zuber, F Zulian, D Lovell… - … England Journal of …, 2012 - Mass Medical Soc
Background Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA;
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods We …
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods We …
[HTML][HTML] Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis
Background Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis
(JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–…
(JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–…